• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Chosa Oncology

0.88 SEK

-2.44 %

Less than 1K followers

CHOSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.44 %
-1.13 %
+13.29 %
-7.58 %
-17.17 %
+29.12 %
-43.91 %
-95.45 %
-93.04 %

Chosa Oncology is a Swedish-Danish biotechnology company that develops solutions for personalized cancer treatment with a focus on diagnostics and drug formulation. The company targets healthcare providers and research actors and works internationally with partners and clinical projects. Chosa Oncology was founded in 2022 and is headquartered in Lund, Sweden.

Read more
Market cap
77.14M SEK
Turnover
204.59K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
27.8.
2026

Interim report Q2'26

19.11.
2026

Interim report Q3'26

25.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release6/1/2026, 6:30 PM

Chosa Oncology AB: CHOSA presents data at ASCO validating Platin-DRP on the NanoString platform showing significant overall survival prediction in Phase III lung cancer study

Chosa Oncology
Regulatory press release6/1/2026, 6:30 PM

Chosa Oncology AB: CHOSA and AIDA present data at ASCO 2026 showing up to 78% pathological complete response (pCR) rate in breast cancer using combined, integrated, taxane and platinum biomarkers

Chosa Oncology
Regulatory press release5/27/2026, 12:40 PM

Bulletin from the annual general meeting on 27 May 2026 in Chosa Oncology AB

Chosa Oncology

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/6/2026, 1:06 PM

Chosa Oncology AB: CHOSA Oncology publishes the Annual and Consolidated Financial Statements for the financial year 2025

Chosa Oncology
Press release4/27/2026, 11:00 AM

Chosa Oncology AB: CHOSA Oncology partners with Mount Sinai, New York to test biomarker guiding platin-immunotherapy in lung cancer

Chosa Oncology
Regulatory press release4/24/2026, 12:30 PM

Notice of annual general meeting in Chosa Oncology AB

Chosa Oncology
Press release4/24/2026, 10:26 AM

Chosa Oncology AB: CHOSA to present new Platin-DRP® data at ASCO 2026

Chosa Oncology
Regulatory press release3/26/2026, 12:00 PM

Chosa Oncology AB: CHOSA presents positive data on Platin-DRP® predicting overall survival in advanced NSCLC at the European Lung Cancer Congress 2026

Chosa Oncology
Press release3/19/2026, 7:45 AM

Chosa Oncology AB: CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress

Chosa Oncology
Press release1/23/2026, 7:33 AM

Chosa Oncology AB: Precision Oncology patent application targeting Platinum Response and Immunotherapy Synergy

Chosa Oncology
Regulatory press release1/19/2026, 7:53 AM

Chosa Oncology AB: CHOSA Oncology AB resolves on a directed issue of units of initially approximately SEK 7.3 million

Chosa Oncology
Regulatory press release12/11/2025, 1:12 PM

Chosa Oncology AB: CHOSA - The market now doubles for Platin-DRP®, which predicts overall survival in lung cancer patients based on NanoString data

Chosa Oncology
Press release11/10/2025, 9:00 AM

Chosa Oncology AB: CHOSA - Platinum chemotherapy is the backbone of PD-1/PD-L1-based lung cancer therapy

Chosa Oncology
Press release10/20/2025, 10:00 AM

Chosa Oncology AB: CHOSA's presented data on the carboplatin response predictor in breast cancer patients on the ESMO conference

Chosa Oncology
Press release10/7/2025, 1:28 PM

Chosa Oncology AB: CHOSA Wins 2025 Jiangning International Entrepreneurship Contest (Greater Shanghai region), China

Chosa Oncology
Regulatory press release9/30/2025, 11:03 AM

Chosa Oncology AB: CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer

Chosa Oncology
Press release8/8/2025, 6:00 AM

Chosa Oncology AB: CHOSA's presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference

Chosa Oncology
Regulatory press release8/1/2025, 12:29 PM

Chosa Oncology AB: Chosa Oncology's warrants of series TO 2 to be admitted to trading

Chosa Oncology
Regulatory press release7/31/2025, 3:25 PM

Chosa Oncology AB: Chosa Oncology announces the last day of trading in BTU

Chosa Oncology
Regulatory press release7/1/2025, 2:19 PM

Chosa Oncology AB: CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study

Chosa Oncology